TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The study population will consist of patients with CAD undergoing PCI. Three key subgroups will be included~2. Willing and able to sign an Institutional Review Board/Ethics Committee (IRB/EC) approved informed consent prior to any study-related activities;~3. Male or female age 18 or greater;~4. If female of childbearing potential, must have a negative urine or serum pregnancy test or be post-menopausal for at least 1 year prior to randomization. Females of childbearing potential must be practicing adequate birth control to be eligible. It is the Investigator's responsibility for determining whether the patient has adequate birth control for study participation;~5. Subject is able and willing to comply with the protocol and all study procedures~Exclusion Criteria:~1. Acute ST-segment elevation myocardial infarction within 48 hours of randomization;~2. Evidence of current clinical instability~3. Evidence of a contraindication to anticoagulation or increased risk of bleeding~4. Use of any investigational drug or device within 30 days of randomization or the planned use of an investigational drug or device through EOS (Day 30 follow-up);~5. Use of the select antithrombotic agents~6. Baseline hemoglobin (Hgb) \<9 g/dL or equivalent;~7. Baseline estimated glomerular filtration rate (GFR) ≤ 10 mL/min/1.73m² or currently undergoing renal replacement therapy (hemodialysis or peritoneal dialysis);~8. Baseline platelet count \<100,000/mm3;~9. Known allergy or intolerance to aspirin, to all available ADP/P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor), or to bivalirudin or REG1 (or any of their respective components);~10. The following planned procedures: a. Planned staged PCI procedure within 3 days after randomization; b. Planned CABG or valve surgery within 30 days after randomization;~11. Any other medical or psychiatric condition that in the Investigator's judgment precludes participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bivalirudin (Type: ACTIVE_COMPARATOR): Bivalirudin bolus and infusion
- Reg 1 (pegnivacogin/anivamersen) (Type: EXPERIMENTAL): Bolus pegnivacogin plus anivamersen active control agent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Finger Individuation Training With a Training Device Versus Conventional Rehabilitation for Writer's Cramp

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* writer's cramp (diagnostic confirmed by a neurologist specialized in movement disorders~* handwriting speed \< 140 letters per minute~* simple or complex writer's cramp~* scholarship in French language~* absence of treatment by botulinum neurotoxin, or last injection \> 3 months~* age \> 18 and \< 71 years~* informed consent~* medical insurance coverage~Exclusion Criteria:~* writer's cramp with no impact on writing~* writing tremor~* other neurological disease with effect on writing~* pain or traumatism of the limb used for writing, requiring medical or surgical treatment in the last preceding months~* participation in another research with a potential impact on evaluation criteria~* pregnant or breast feeding patient~* patient under judiciary protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Finger individuation training (Type: EXPERIMENTAL): Finger Force Manipulandum
- control (Type: ACTIVE_COMPARATOR): conventional physiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease (COPD) Exacerbation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients ≥ 40 years and \< 80 years admitted to the hospital via ER~2. COPD at least Gold II~3. At least 10 pack years of smoking history~4. Physical therapy is tolerated, outside pulmonary rehabilitation~Exclusion Criteria:~1. Rehabilitation program \< 1 year~2. Intolerance to prednisone~3. Non-compliance~4. Comorbidity limiting pulmonary rehabilitation~5. History of asthma~6. Prior randomisation~7. Findings on X thorax other than fitting with COPD

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- interventional, rehabilitation (Type: EXPERIMENTAL): 'early pulmonary lung rehabilitation'
- control (Type: NO_INTERVENTION): standard care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Combined Vitrectomy and Triamcinolone in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Macular edema secondary to BRVO~* Best Corrected Visual Acuity of ≤ 20/40 on ETDRS chart~* Duration no shorter than 3 months~* Duration no longer than 12 months~Exclusion Criteria:~* Proliferations in study eye~* Blod in vitreous cavity~* Previous fundus laser treatment~* BRVO with over 180˚ of ischemia on FA~* Age under 18~* Other eye condition which contribute to relevant loss of visual acuity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Grid Laser
- 2 (Type: EXPERIMENTAL): Vitrectomy in combination with 20 mg triamcinolone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study of Lyzme5 Impact on Cholesterol and Body Weight in Man

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 21 years of age or older;~* Able to read, understanding, and signing a consent form;~* Not pregnant or breast feeding (female only);~* Have normal bio-markers for liver and kidney function (determined by blood test);~* Being at least 15 lbs over your ideal weight as defined by the Body Mass Index \[BMI\] chart;~* Have a total cholesterol level of or in excess of 200 mg/dl (determined by blood test);~* Not using any illegal substances, including marijuana (medicinal or otherwise);~* Not using any recreational drugs~* Weighing less than 300 lbs~Exclusion Criteria:~* Under 21 years of age;~* Mentally impaired;~* Pregnant or breast feeding;~* A diabetic;~* Having digestion problems;~* Problems with kidneys, heart, or liver;~* Having, or have had cancer;~* Taking a prescription;~* Weight of 300 lbs or over;~* Total cholesterol under 200 mg/dl;~* Using recreational drugs.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Overweight, elevated total cholesterol (Type: PLACEBO_COMPARATOR): All individuates enrolled in this study are at least 15 lbs over their ideal weight as described on a BMI chart. Each individual must also have a total cholesterol of at least 200 mg/dl, or higher.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Celebrex Total Knee Arthroplasty Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject is a male or female 18 years or older with osteoarthritis of the knee scheduled to undergo elective unilateral primary total knee arthroplasty because of OA, performed under a standardized regimen of anesthesia and procedure.~Exclusion Criteria:~* Subject has a history of inflammatory arthritis (e.g. rheumatoid arthritis, ankylosing spondylitis) other than osteoarthritis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Celecoxib (Type: EXPERIMENTAL): Celecoxib
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of the Use of Sodium Pyruvate Bronchodilation in Asthmatics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. A physician diagnosis of asthma~2. Age years old~3. Symptoms consistent with asthma for at least 6 months~4. Current asthma medications: Short-acting inhaled beta agonists as needed for control of asthma symptoms with or without a low to medium dose of an ICS, as defined in the table below and if on a ICS may also be on a long-acting beta agonist provided it is withheld for 24 hours prior to the testing days.~   Inhaled Corticosteroid Dose less than or equal to:~   Beclomethasone-HFA 480 µg/day Budesonide-DPI 1000 µg/day Flunisolide 2000 µg/day Fluticasone 500 µg/day Triamcinolone 2000 µg/day~5. FEV1 at screening 50-80% predicted (Hankinson6)~6. Reversibility with albuterol of 12% and 200 ml FEV1FEV1 at 30 minutes.~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of a Catheter-based Ultrasound Hyperthermia System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are to be given HDR brachytherapy for treatment of solid tumor of the following:~  * Cervical cancer Stage III or IV OR~ * Prostate cancer (with rising prostate specific antigen after prior local therapy)~* Age \>=18 years~* Eligible for brachytherapy as determined per clinical standard of care.~* Ability to give written informed consent and willingness to comply with the requirements of the protocol~Exclusion Criteria:~* Patients who are not candidates for HDR brachytherapy~* Any condition that compromises compliance with the objectives and procedures of this protocol, as judged by the principal investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hyperthermia with HDR brachytherapy (Type: EXPERIMENTAL): Hyperthermia will be delivered within approximately 2 hours of (HDR) brachytherapy associated with the implant session

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness Study of the BioVac Direct Suction Device in Upper Gastrointestinal Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Patients presenting with fresh blood hematemesis, coffee ground emesis, or melena~2. Patients with hematochezia and hypotension (systolic blood pressure \< 90 mm Hg) or tachycardia (heart rate \> 110 beats per minute)~Exclusion Criteria~1. Identification of a bleeding source within the first 5 minutes of the upper endoscopy or no blood seen in the upper GI tract as these patients do not require additional suctioning.~2. Age \< 18.~3. No endoscopy was performed.~4. Endoscopy previously performed for current episode of UGIB.~5. Patients unable to consent and who do not have a substitute decision maker.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BioVac Direct Suction Device (Type: EXPERIMENTAL): Experimental arm
- Standard Endoscopy Suction (Type: ACTIVE_COMPARATOR): Control arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Immune Activation as a Cause of Insulin Resistance in Adults Living With HIV-1 on Effective Antiretroviral Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Subject consulting or hospitalized in the tropical and infectious diseases unit at the University Hospital of Montpellier that have been enrolled in a study during which the immune activation profile was analyzed~* Subject aged at least 18 years~* Subject speaking french fluently~* Subject who is not opposed to participate to the study, after a clear information~* Subject affiliated to a social security system~* Infection by HIV-1 determined by a positive serology or by a measure of the plasma viral load (RNA HIV)~* HIV-1 patients under stable antiretroviral therapy~* HIV load \< 50 copies/mL since at least 6 months before enrollment (2 measures)~Exclusion criteria:~* Vulnerable individuals~* Persons protected~* Pregnant women or breastfeeding mothers~* Bad understanding of the nature and goals of the study and/or communication difficulties with the investigator~* Subject enrolled in an other study with an exclusion period still running~* Non infectious pathology that might be the origin of an immune anomaly~* Treatment by an immune modulator molecule or by chemotherapy in the 60 days before enrollment in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non viremic HIV patients under treatment (Type: None): Patients with various immune activation profiles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Endodrill vs. Conventional Biopsy. Diagnostics and Genetic Analysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with adenocarcinoma of the distal esophagus/cardia or stomach capable of stating a formal consent to participate in the study.~Exclusion Criteria:~* Mental illness~* Extreme co-morbidity (ASA \>3)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Conventional biopsy (Type: ACTIVE_COMPARATOR): 4 out of 8 biopsies taken with a conventional biopsy forceps from the tumor tissue in the distal esophagus and cardia. The biopsies will be taken in random order blinded for the person performing the examination. 1 additional biopsy will be taken from the tumor tissue in order to be evaluated for appropriateness of further genetic analysis. Both type of biopsies will be taken from the same patient. In total 10 biopsies per patient.
- Endodrill biopsy (Type: ACTIVE_COMPARATOR): 4 out of 8 biopsies taken with the Endodrill instrument from the tumor tissue in the distal esophagus and cardia. The biopsies will be taken in random order blinded for the person performing the examination. 1 additional biopsy will be taken from the tumor tissue in order to be evaluated for appropriateness of further genetic analysis. Both type of biopsies will be taken from the same patient. In total 10 biopsies per patient.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Aerosolized Plus Intravenous vs. Intravenous Colistin for VAP Due to Pandrugs-resistant A. Baumannii in Neonates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Neonates who are admitted to the neonatal intensive care unit, Hat Yai Hospital during the study period.~* Neonates who were complicated with VAP due to PDR-Acinetobacter baumannii susceptible to colistin (by minimal inhibitory concentration (MIC) \< 2 mcg/dL).~Exclusion Criteria:~* Neonates who have a major anomaly or chromosomal abnormality.~* Neonates who receive colistin prior 7 days prior to study.~* Neonates who have a significant renal dysfunction defined as a serum creatinine (SCr) \>1.5 mg/dL or a decrease in urine output to \< 1 mL/kg/h;

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 30 Days
- Healthy Volunteers: f

Study Arms:
- Aerosolized plus intravenous colistin (Type: EXPERIMENTAL): Neonates with VAP due to PDR-A. baumannii who receive aerosolized colistin (4 mg/kg/dose twice daily) plus intravenous colistin (3.5 mg/kg/dose twice daily)
- Intravenous colistin (Type: ACTIVE_COMPARATOR): Neonates with VAP due to PDR-A. baumannii who receive only intravenous colistin (3.5 mg/kg/dose twice daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of a Low Residue Diet in Comparison to the Dietetic Recommendations From the INCan in Cervical Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women 18 years of age and older.~* Ability to understand the study and be able to sign the informed consent.~* Functional stage ECOG 0 - 2.~* Negative pregnancy test, null reproductive potential, or currently using an contraceptive method.~* Willing and able to attend the programmed visits.~* Diagnosed with cervical malignant tumors of epithelial origin in the neck of the uterus, clinical stages IB2-IVA.~* Candidates to receive concomitant Chemo-Radiotherapy, followed by Brachytherapy.~* In case of presence of diabetes mellitus and/or hypertension, without retinopathy or albuminuria \<300 mg/dl.~* In case of renal deterioration, a creatinine clearance \>20 ml/min.~* Hemoglobin \>10 g/l.~* Leucocytes \> 4000/mm3.~* Platelets \>100000/mm3.~Exclusion Criteria:~* Under a different nutritional treatment using a nutritional supplement.~* Carrying other uncontrolled diseases, including cardiovascular insufficiency, arrhythmia, psychiatric illnesses.~* Concomitant treatment with another experimental drug.~* Active TB.~* Infected with HIV.~* History of LES and other rheumatologic diseases that involve renal deterioration.~* Presence of vesicular-vaginal fistulae at moment of diagnosis.~* Previous malignancy.~Study Discontinuation Criteria:~* Loss of follow up for 21 days.~* Evidence of disease progression.~* At the request of patient.~* By unacceptable toxicity.~* Pregnancy.~Criteria must be followed punctually. If a patient were inappropriately included, she must be discontinued from the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dietary modification (Type: EXPERIMENTAL): Personalized dietary intervention, low residue diet
- Control (Type: NO_INTERVENTION): Dietary recommendations currently used in the INCan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues